肥大细胞在粘膜抗感染免疫中的作用

近年来研究资料表明,肥大细胞参与获得性免疫应答,提供对ＣＤ４＾＋和ＣＤ８＾＋Ｔ细胞的协同刺激,并可释放对Ｂ细胞的殖和分化信号。这些功能在细菌性感染和线虫感染中均有其表现,并与这些感染的免疫防护有关,肥大细胞可通过启动或控制对抗细菌或寄生虫感染的Ｔ和Ｂ细胞表型来完成其对特异性免疫调节功能。对于肥大细胞功能的深入了解将有助于许多生理及免疫病理机制的阐明。     

肥大细胞在动脉粥样硬化形成中的作用

动脉粥样硬化,是冠心病的病理基础,被认为是一种慢性炎症性疾病,涉及如巨噬细胞和T淋巴细胞等许多炎性细胞。肥大细胞是一种重要的免疫细胞,其功能主要是在超敏反应方面的作用。有病理学研究表明:肥大细胞在动脉粥样硬化斑块周围表达增加,这表明肥大细胞可能与疾病的进展有关。最近的研究表明,肥大细胞在动脉粥样硬化中确实起着重要的作用。本文通过总结肥大细胞在动脉粥样硬化形成中的作用,为在疾病进程中,通过调节肥大细胞功能来改善动脉粥样硬化的这种治疗方式的可能性提供依据。     

肥大细胞在动脉粥样硬化形成中的作用

动脉粥样硬化,是冠心病的病理基础,被认为是一种慢性炎症性疾病,涉及如巨噬细胞和T淋巴细胞等许多炎性细胞。肥大细胞是一种重要的免疫细胞,其功能主要是在超敏反应方面的作用。有病理学研究表明：肥大细胞在动脉粥样硬化斑块周围表达增加,这表明肥大细胞可能与疾病的进展有关。最近的研究表明,肥大细胞在动脉粥样硬化中确实起着重要的作用。本文通过总结肥大细胞在动脉粥样硬化形成中的作用,为在疾病进程中,通过调节肥大细胞功能来改善动脉粥样硬化的这种治疗方式的可能性提供依据。     

IgE介导的肥大细胞脱颗粒信号转导途径的研究进展

肥大细胞(mast cell,MC)是过敏性疾病的关键细胞之一.机体的过敏反应很大程度依赖于肥大细胞膜上的特异性受体FcεRI.肥大细胞膜上交联的FcεRI引发了下游的一系列信号事件并导致脱颗粒,包括细胞因子及趋化因子产生以及白三烯的释放.由于IgE在过敏反应中的重要作用,现在的研究主要集中在FcεRI下游的信号事件.其脱颗粒的分子机制是一个由多种蛋白质分子介导的,各个环节受到精确调控的复杂过程.对肥大细胞脱颗粒分子机制的深入研究将给过敏性疾病提供一个新的治疗方案.     

ADCC效应在抗HIV感染中的作用

抗体依赖性细胞介导的细胞毒性作用(antibody-dependent cell-mediated cytotoxicity,ADCC)是一种固有免疫和适应性免疫相结合的免疫学效应。ADCC效应主要是通过效应细胞膜表面的受体IgG Fc受体(Fc receptor,FcR)如FcγRIIIa(CD16)、FcγRIIc(CD32)、FcγRI(CD64)识别靶细胞膜表面抗原,结合相应IgG抗体的Fc段而促发效应细胞脱颗粒和细胞因子分泌的一类细胞毒效应。对人类免疫缺陷病毒(human immunodeficiency virus,HIV)感染已有研究证实了,ADCC效应在控制HIV感染中发挥着重要作用。现对ADCC效应在抗HIV感染中的作用作一综述。     

肥大细胞在病毒感染中的作用

自从Paul Ehrlich于1878年首次发现肥大细胞以来,肥大细胞作为过敏反应中非常重要的效应细胞之一被广泛研究。直到近20年,人们才逐渐认识到肥大细胞参与多种病理、生理过程,尤其是在机体抗感染、免疫与免疫病理损伤中也发挥着重要作用。随着人们对肥大细胞在细菌和寄生虫的抗感染、免疫中作用的理解不断深入,肥大细胞在病毒感染及病毒引起的相关疾病中的作用逐渐成为备受关注的研究热点,现就肥大细胞在不同病毒感染中的作用作一综述。     

肥大细胞在脂肪组织中的作用

肥大细胞(mast cells)起源于骨髓造血干细胞,定植到机体各个外周组织后继续发育成熟,在过敏性反应和预防微生物感染等方面发挥重要作用。近来研究发现,肥胖患者的脂肪组织含有大量肥大细胞,引发人们对脂肪组织中肥大细胞作用的关注。肥大细胞可释放出多种生物活性介质,作用于脂肪组织,影响脂肪组织中细胞外基质的重塑和各种炎性细胞的活动。更多研究还表明肥大细胞可能参与到肥胖、糖尿病等代谢性疾病的发病机理,影响疾病的进展。本文总结近年来对脂肪组织中肥大细胞研究的一系列成果,对肥大细胞在脂肪组织中的生物学作用进行综述。     

肥大细胞在肿瘤发生发展中的作用

肥大细胞是人体主要免疫细胞之一,因其作为导致过敏反应发生的最直接效应细胞而著称.肥大细胞最主要的结构特征为其胞内含有大量嗜碱性颗粒,该颗粒内又富含种类众多的生物活性物质,包括组胺、血管内皮生长因子(vascular endothelial growth factor,VEGF)、成纤维细胞生长因子(fibroblast...     

胃促胰酶和肥大细胞在豚鼠过敏性休克死亡的应用

目的:建立豚鼠过敏性休克模型,研究胃促胰酶和肥大细胞在过敏性休克诊断上的应用。方法:20只清洁级豚鼠随机分为10只实验组和10只对照组,应用混合人血清构建的过敏模型,ELISA方法测定豚鼠血清Ig E含量,免疫组化染色观察胃促胰酶在喉头、气管、肺、胃、肠的表达,肥大细胞特殊染色计数肥大细胞。结果:实验组豚鼠有70%发生过敏性休克死亡,实验组豚鼠血清中Ig E的含量显著高于对照组豚鼠(P0.05),实验组豚鼠于喉头、气管、肺胃促胰酶的表达高于对照组(P0.05),实验组豚鼠于喉头、气管、肺、胃的肥大细胞总数高于对照组豚鼠(P0.05),肺组织观察到肥大细胞脱颗粒。结论:胃促胰酶和肥大细胞可以为过敏性休克死亡的法医学鉴定提供参考。     

Immunoglobulin E-independent activation of mast cell is mediated by Mrg receptors

Mast cells play a central role in inflammatory and allergic reactions by releasing inflammatory mediators through two main pathways, immunoglobulin E-dependent and -independent activation. In the latter, mast cells are activated by a diverse range of basic molecules, including peptides and amines such as substance P, neuropeptide Y, and compound 48/80. These secretagogues are thought to activate the G proteins in mast cells through a receptor-independent mechanism. Here, we report that the basic molecules activate G proteins through the Mas-related gene (Mrg) receptors on mast cells, leading to mast cell degranulation. We suggest that one of the Mrg receptors, MrgX2, has an important role in regulating inflammatory responses to non-immunological activation of human mast cells.     

糖皮质激素对肥大细胞胞膜流动性的影响

目的:研究糖皮质激素(皮质酮)对肥大细胞胞膜流动性的快速作用。方法:采用荧光偏振法检测膜流动性,检测不同浓度皮质酮对肥大细胞膜流动性的快速影响以及加用糖皮质激素受体拮抗剂RU38486看其是否影响皮质酮对肥大细胞膜流动性的快速作用。结果:与阴性对照组比较,皮质酮能够在7min内剂量依赖性地快速降低肥大细胞胞膜流动性,稳定肥大细胞胞膜(P0.01);加用糖皮质激素受体拮抗剂RU38486后能部分阻断皮质酮对肥大细胞膜流动性的快速作用(P0.01)。结论:糖皮质激素能够快速降低肥大细胞胞膜流动性,稳定肥大细胞胞膜,这一作用可能是糖皮质激素快速抑制肥大细胞脱颗粒非基因组机制作用的靶点之一。     

The effects of co-culture of fibroblasts on mast cell exocytotic release characteristics as evaluated by carbon-fiber microelectrode amperometry

In this work, carbon-fiber microelectrode amperometry (CFMA) is employed to probe changes in the biophysical mechanism of exocytosis under varied cell culture conditions. Degranulation and serotonin exocytosis from mouse peritoneal mast cells (MPMCs) were measured both without and with co-cultured Swiss-albino 3t3 fibroblasts using CFMA. After 24 h in culture, there are distinct differences in the exocytotic characteristics of MPMCs cultured with and without fibroblast support cells, as detected by CFMA, including an increased number of secreted serotonin molecules, number of granule fusion events, secretion rate, and granule membrane tension. Beyond 48 h in culture, MPMCs cultured alone cannot be analyzed using CFMA due to decreased viability and membrane tension whereas MPMCs co-cultured with fibroblasts were maintained for up to 28 days in culture. Some secretion characteristics evolved over the long-term co-culture but the total amount of serotonin released per cell remained largely constant. This work quantitatively demonstrates that the MPMC/fibroblast co-culture system presents a promising model system for chronic exposure or disease model studies based on CFMA analysis.     

The plasma membrane shuttling of CAPRI is related to regulation of mast cell activation

The Ca(2+)-promoted Ras inactivator (CAPRI), a Ras GTPase-activating protein, is involved in the inactivation of mitogen-activated protein kinase pathway. However, a precise role of CAPRI in immune responses is still unknown. Here we showed that overexpression of CAPRI suppresses antigen-induced degranulation and cytokine production in mast cells (RBL cells). Antigen elicited the translocation of CAPRI to the plasma membrane from the cytoplasm, which was concomitant with the increase in the intracellular Ca(2+) concentration. The nuclear import of extracellular signal-regulated kinase 2 (ERK2) occurred after the re-localization of CAPRI to the cytoplasm in the mast cells, suggesting that the early phase of ERK2 activation is eliminated. A mutant of GAP-related domain, CAPRI(R472S), showed a feeble translocation to the plasma membrane but did not affect the degranulation, ERK2 activation, and cytokine production. The results suggested that the translocation of CAPRI to the plasma membranes regulates crucially cellular responses in mast cells.     

Rapid lineage-specific diversification of the mast cell chymase locus during mammalian evolution

Serine proteases constitute the major protein granule content of cells of several hematopoietic cell lineages. A subgroup of these proteases, including the mast cell chymases, neutrophil cathepsin G, and T cell granzymes B to F and N, are in all investigated mammals encoded in one locus, the chymase locus. It is interesting to note that this locus has diversified greatly during the last 95 Myr of mammalian evolution. This divergence is exemplified by the presence of Mcpt8-related genes and multiple β-chymases in the mouse and rat, which lack direct counterparts in primates and in seven functional granzyme genes in the mouse where the human locus has only two. To study the expansion of the locus during rodent evolution and to better understand the evolutionary origin of β-chymases and the Mcpt8-family, we have performed a detailed analysis of the chymase locus of four mammalian species, i.e., human, dog, mouse, and rat. As a result, we report here a second chymase-like gene in dog, Cma2, which clusters with β-chymases in phylogenetic analyses. This finding supports a duplication of the common ancestor for α- and β-chymases before the major radiation of placental mammals, and a loss of the ancestral β-chymase gene sometime during primate evolution. Moreover, we show that in the rat, the Mcpt8-family diversified relatively recently together with sequences related to the β-chymase Mcpt2. Eight novel genes were identified in the duplication region, four of which are predicted to be functional. Duplications of rat granzyme B- and C-like sequences occurred seemingly independently within a similar time frame, but did not give rise to functional genes. Due to the duplications in rat and deletions in the carnivore/primate lineage, the rat chymase locus is approximately 15 and 9 times larger than its counterparts in dog and human, respectively. These findings illustrate the importance of gene duplications in conferring rapid changes in mammalian genomes.     

Further studies on the structural requirements for mast cell degranulating (MCD) peptide-mediated histamine release

Mast cell degranulating (MCD) peptide was modified in its two disulfide bridges and in the two arginine residues in order to measure the ability of these analogs to induce histamine release from mast cells in vitro. Analogs prepared were [Ala^3,15]MCD, [Ala^5,19]MCD, [Orn¹⁶]MCD, and [Orn^7,16]MCD. Their histamine-releasing activity was determined spectrofluorometrically with peritoneal mast cells. The monocyclic analogs in which the cysteine residues were replaced pairwise with alanine residues showed three-to ten-fold diminished histamine-releasing activity respectively, compared with the parent MCD peptide. Substantial increases in activity were observed where arginine residues were replaced by ornithines. The ornithine-mono substituted analog showed an almost six-fold increase and the ornithine-doubly substituted analog three-fold increase in histamine-releasing activity compared with the parent MCD peptide. The structural changes associated with these activities were followed by circular dichroism (CD) spectroscopy. Changes in the shape and ellipticity of the CD spectra reflected a role for the disulfide bonds and the two arginine residues in the overall conformation and biological activity of the molecule.     

Identification of lysophosphatidylthreonine with an aromatic fatty acid surrogate as a potent inducer of mast cell degranulation

Upon various stimulations, mast cells (MCs) release a wide variety of chemical mediators stored in their cytoplasmic granules, which then initiates subsequent allergic reactions. Lysophosphatidylserine (LysoPS), a kind of lysophospholipid, potentiates the histamine release from MCs triggered by antigen stimulation. We previously showed through structure-activity studies of LysoPS analogs that LysoPS with a methyl group at the carbon of the serine residue, i.e., lysophosphatidylthreonine (LysoPT), is extremely potent in stimulating the MC degranulation. In this study, as our continuing study to identify more potent LysoPS analogs, we developed LysoPS analogs with fatty acid surrogates. We found that the substitution of oleic acid to an aromatic fatty acid surrogate (C3-pH-p-O-C11) in 2-deoxy-1-LysoPS resulted in significant increase in the ability to induce MCs degranulation compared with 2-deoxy-1-LysoPS with oleic acid. Conversion of the serine residue into the threonine residue further increased the activity of MC degranulation both in vitro and in vivo. The resulting super agonist, 2-deoxy-LysoPT with C3-pH-p-O-C11, will be a useful tool to elucidate the mechanisms of stimulatory effect of LysoPS on MC degranulation.     

Hydroxytyrosol and oleuropein of olive oil inhibit mast cell degranulation induced by immune and non-immune pathways

The aim of this study was to determine whether hydroxytyrosol and oleuropein, the major phenols found in olives and olive oil, inhibit mast cell activation induced by immune and non-immune pathways. Purified peritoneal mast cells were preincubated in the presence of test compounds (hydroxytyrosol or oleuropein), before incubation with concanavalin A, compound 48/80 or calcium ionophore A23187. Dose–response and time-dependence studies were carried out. Comparative studies with sodium cromoglycate, a classical mast cell stabilizer, were also made. After incubation the supernatants and pellets were used to determine the β-hexosaminidase content by colorimetric reaction. The percentage of β-hexosaminidase release in each tube was calculated and taken as a measure of mast cell activation. Other samples of cell pellets were used for cell viability studies by the trypan blue dye exclusion test, or fixed for light and electron microscopy. Biochemical and morphological findings of the present study showed for the first time that hydroxytyrosol and oleuropein inhibit mast cell degranulation induced by both immune and non-immune pathways. These results suggest that olive phenols, particularly hydroxytyrosol and oleuropein, may provide insights into the development of useful tools for the prevention and treatment of mast cell-mediated disorders.